Workflow
*ST天山(300313) - 2022 Q3 - 季度财报
TIANSHAN BIOTIANSHAN BIO(SZ:300313)2022-10-24 16:00

Financial Performance - The company's revenue for Q3 2022 was ¥17,410,920.69, representing a decrease of 14.39% compared to the same period last year[5] - The net profit attributable to shareholders was -¥16,273,102.20, a decline of 42.37% year-on-year[5] - The net profit after deducting non-recurring gains and losses was -¥7,716,932.62, showing an improvement of 31.12% compared to the previous year[5] - The company reported a 23.84% decrease in year-to-date revenue, totaling ¥46,438,688.52, primarily due to the timing of livestock sales and pandemic-related market closures[12] - Total operating revenue for the third quarter was ¥46,438,688.52, a decrease of 23.8% compared to ¥60,974,559.03 in the same period last year[33] - The net loss for the period was ¥28,568,998.45, compared to a net loss of ¥22,757,074.87 in the previous year, representing a 25.5% increase in losses[34] - The total comprehensive loss for the period was ¥16,588,702.09, compared to a loss of ¥27,814,845.50 in the previous year[34] Assets and Liabilities - Total assets at the end of the reporting period were ¥788,347,788.01, down 6.46% from the end of the previous year[5] - The company's current assets decreased to CNY 127,503,149.28 from CNY 172,594,314.35, representing a reduction of about 26.1%[31] - The company's cash and cash equivalents dropped to CNY 70,520,414.30 from CNY 108,882,819.76, indicating a decline of approximately 35.2%[31] - Accounts receivable decreased significantly from CNY 27,118,081.66 to CNY 4,817,356.16, a reduction of about 82.2%[31] - Total liabilities decreased to CNY 690,702,465.88 from CNY 728,431,283.02, showing a decline of approximately 5.2%[32] - The company's total equity decreased to CNY 97,645,322.13 from CNY 114,359,369.77, reflecting a decline of about 14.6%[32] Cash Flow - Cash flow from operating activities for the year-to-date was -¥2,760,039.21, reflecting a significant decline of 202.61%[5] - The company reported a net cash outflow from operating activities of ¥2,760,039.21, contrasting with a net inflow of ¥2,689,846.42 in the same quarter last year[37] - Cash inflow from financing activities increased by 92.99% to ¥124,480,000.00, attributed to refinancing strategies[15] - The company experienced a significant increase in cash inflow from financing activities, totaling ¥124,480,000.00, compared to ¥64,500,000.00 in the previous year[37] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,010[17] - The largest shareholder, Huzhou Haohui Enterprise Management Consulting Co., Ltd., holds 22.11% of the shares, totaling 69,211,312 shares, with 26,350,000 shares pledged[20] - Chen Dehong, a significant shareholder, holds 11.91% of the shares, totaling 37,279,083 shares, with 36,509,768 shares pledged and all shares frozen[22] - The company’s major shareholder, Huzhou Haohui, has 38.07% of its shares pledged, which represents 8.42% of the total shares outstanding[20] Legal and Operational Issues - The company has been unable to exercise control over Daxiang Advertising due to legal issues involving its former actual controller, Chen Dehong, who is under criminal investigation[19] - The company’s control measures over Daxiang Advertising have been obstructed, preventing it from consolidating Daxiang Advertising into its financial statements[19] - The company has ongoing litigation regarding equity transfer disputes involving 33 parties, with no judgment rendered as of the latest update[29] - The company continues to monitor its financial position and is exploring strategies for market expansion and potential restructuring[29] Impairment and Development - The company has recognized an impairment provision of RMB 28.69 million due to changes in agricultural land use and water resource management policies affecting its farming operations[25] - The company’s agricultural development land area is expected to decrease to 23,940 acres in 2022 due to government water allocation adjustments[25] Expenses - Total operating costs amounted to ¥67,220,917.63, down 20.0% from ¥84,936,720.19 year-on-year[33] - Research and development expenses increased to ¥361,344.55, up from ¥106,752.77, indicating a focus on innovation[33] - The company incurred financial expenses of ¥11,824,955.02, which is an increase from ¥10,105,895.30 year-on-year[33]